SCZ-PRS have been repeatedly linked to various measures of psychosis, psychotic symptoms and experiences, within clinical and general population samples. Associations with negative and positive symptoms have also been noted. For instance, Jones et al (2016) report that SCZ-PRS are associated with 0.5–0.7% of the variance in psychotic experiences at ages 12–18. In addition, SCZ-PRS have been linked to chronicity and course of illness with one study finding SCZ-PRS to predict the number of hospital admissions, length of hospital stay and enrollment in supportive housing (Meier et al., 2016). Mixed evidence also exists for an effect of SCZ-PRS on treatment response (Wimberley et al., 2017b, Li et al., 2017). Interestingly, the predictive utility for antipsychotic response is improved by incorporating rare variants into such scores (Ruderfer et al., 2016), although null findings also exist (e.g., (Hettige et al., 2016)). Family history also accentuates risk conferred by SCZ-PRS (Agerbo et al., 2015).
